Nykode Therapeutics Share Price
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Oslo Bors
15:45:00 25/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 3.905 NOK | +2.36% |
|
-2.86% | +61.90% |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
| Market Cap | 1.28B 134M 118M 111M 101M 190M 12.87B 191M 1.33B 516M 6.57B 504M 493M 21.13B | P/E 2026 * |
-5.99x | P/E 2027 * | 80.5x |
|---|---|---|---|---|---|
| Enterprise Value | 791M 83.29M 73.08M 69.02M 62.9M 118M 7.98B 119M 826M 320M 4.08B 313M 306M 13.11B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.08x |
| Free-Float |
76.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Börse Stuttgart
| 5VB | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
CBOE
| Real-time |
Last Transcript: Nykode Therapeutics
| 1 day | +2.36% | ||
| 1 week | -2.86% | ||
| Current month | -8.97% | ||
| 1 month | -14.36% | ||
| 3 months | +21.09% | ||
| 6 months | +27.95% | ||
| Current year | +61.90% |
| 1 week | 3.8 |  | 4.18 |
| 1 month | 3.76 | | 5.2 |
| Current year | 2.21 | | 5.2 |
| 1 year | 1.58 | | 5.2 |
| 3 years | 1.44 | | 26.64 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 31/12/2018 |
| President | 49 | 31/12/2016 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 02/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 22/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/03/25 | Buy | Company | 3,000,000 | 0.9187% | ||
| 20/12/24 | Buy | Director | 100,000 | 0.0306% | ||
| 20/12/24 | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.36% | -2.86% | +146.68% | -86.05% | 131M | |
| -3.30% | +1.19% | +54.62% | +104.15% | 71.94B | |
| +1.25% | -2.63% | +35.88% | +77.04% | 59.35B | |
| +2.12% | +5.79% | +32.63% | +24.27% | 27.16B | |
| -3.06% | -4.96% | -16.43% | +350.25% | 26.54B | |
| -0.75% | -0.14% | -1.23% | -5.85% | 24.93B | |
| +0.40% | +1.47% | +21.93% | -9.96% | 20.61B | |
| -1.70% | -3.35% | +146.86% | +325.69% | 15.03B | |
| +0.21% | +1.21% | -6.26% | +493.02% | 14.2B | |
| +0.36% | -0.56% | +49.47% | +170.76% | 14.36B | |
| Average | -0.21% | -0.62% | +46.42% | +144.33% | 27.43B | |
| Weighted average by Cap. | -0.78% | -0.25% | +35.66% | +131.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 210M 22.11M 19.4M 18.32M 16.7M 31.25M 2.12B 31.48M 219M 84.91M 1.08B 83M 81.2M 3.48B |
| Net income | -209M -22.06M -19.35M -18.28M -16.66M -31.18M -2.11B -31.41M -219M -84.72M -1.08B -82.81M -81.02M -3.47B | 9.97M 1.05M 921K 870K 792K 1.48M 101M 1.49M 10.41M 4.03M 51.38M 3.94M 3.85M 165M |
| Net Debt | -484M -50.98M -44.73M -42.25M -38.5M -72.07M -4.89B -72.59M -506M -196M -2.5B -191M -187M -8.02B | -628M -66.17M -58.06M -54.84M -49.97M -93.55M -6.34B -94.22M -656M -254M -3.24B -248M -243M -10.41B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/09/26 | NOK 3.905 | +2.36% | 1,455,737 |
| 24/09/26 | NOK 3.815 | -3.05% | 1,436,951 |
| 23/09/26 | NOK 3.935 | -2.36% | 629,340 |
| 22/09/26 | NOK 4.030 | +1.51% | 896,598 |
| 21/09/26 | NOK 3.970 | -1.98% | 1,206,542 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
